Illicit organogenesis: Methods and substances of doping and manipulation

Organogenesis

Volumn 4, Issue 4, 2008, Pages 264-271

  Thevis, Mario ^a   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Anabolics; Doping; HIF; Insulin; Mass spectrometry; S107; Sport

Indexed keywords

CALCIUM CHANNEL; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1; INSULIN; RYANODINE RECEPTOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SYNTHETIC INSULIN;

DOPING; DRUG MISUSE; HUMAN; MUSCLE CELL; NONHUMAN; ORGANOGENESIS; PHYSICAL PERFORMANCE; REVIEW; SPORT;

EID: 57349182202     PISSN: 15476278     EISSN: 15558592     Source Type: Journal    
DOI: 10.4161/org.4.4.7286     Document Type: Review

References (57)

1. Toohey K, Veal AJ. The Olympic Games - A social science perspective. CABI Publishing: Oxon - New York 2000.
2. World Anti-Doping Agency. The 2008 Prohibited List 2008; www.wada-ama.org/rtecontent/document/2008_List_En.pdf.
3. Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem 2002; 311:119-26.
4. Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000; 405:635.
5. Thevis M, Schänzer W. Identification and Characterization of Peptides and Proteins in Doping Control Analysis. Curr Proteomics 2005; 2:191-208.
6. Pascual J, Belalcazar V, de Bolos C, Gutierrez R, Llop E, Segura J. Recombinant erythropoietin and analogues: a challenge for doping control. Ther Drug Monit 2004; 26:175-9.
7. Kohler M, Ayotte C, Desharnais P, Flenker U, Lüdke S, Thevis M, Völker-Schänzer E, Schänzer W. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int J Sports Med 2008; 29:1-6.
8. Holt RI, Sonksen PH. Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol 2008; 154:542-56.
9. Thevis M, Geyer H, Mareck U, Schänzer W. Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. J Mass Spectrom 2005; 40:955-62.
10. Thevis M, Schänzer W. Emerging Drugs-Potential for misuse in sport and doping control detection strategies. Mini-Rev Med Chem 2007;7:533-9.
11. Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, Montori VM, Gao W, Dalton JT. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2:146-59.
12. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, Miller DD. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 1998;244:1-4.
13. GTx, Inc. Ostarine achieved the primary endpoint of increasing lean body mass and a secondary endpoint of improving functional performance 2006; www.salesandmarketingnetwork.com/news_release.php?ID=2015328.
14. Thevis M, Schänzer W. Mass spectrometry of selective androgen receptor modulators. J Mass Spectrom 2008; 43:865-76.
15. Thevis M, Kamber M, Schänzer W. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes. Rapid Commun Mass Spectrom 2006; 20:870-6.
16. Thevis M, Kohler M, Schlörer N, Kamber M, Kuhn A, Linscheid MW, Schänzer W. Mass spectrometry of hydantoin-derived selective androgen receptor modulators. J Mass Spectrom 2008; 43:639-50.
17. Thevis M, Kohler M, Thomas A, Maurer J, Schlörer N, Kamber M, Schänzer W. Determination of benzimidazole- and bicyclic hydantoin-derived selective androgen receptor antagonists and agonists in human urine using LC-MS/MS. Anal Bioanal Chem 2008; 391:251-61.
18. Thevis M, Kohler M, Maurer J, Schlörer N, Kamber M, Schänzer W. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis. Rapid Commun Mass Spectrom 2007; 21:3477-86.
19. Thevis M, Kohler M, Schlörer N, Fusshöller G, Schänzer W. Detection of 2-quinolinone-derived SARMs using GC-MS and LC-MS/MS, in Recent Advances in Doping Analysis (Schänzer W, Geyer H, Gotzmann A and Mareck U, Eds.), Sport&Buch Strauss, Cologne 2008.
20. Thevis M, Kohler M, Thomas A, Schlörer N, Schänzer W. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22:2471-8.
21. International Diabetes Federation. Diabetes epidemic out of control 2006; www.idf.org/home/index.cfm?unode=7F22F450-B1ED-43BB-A57C-B975D16A812D.
22. Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349:47-51.
23. Thevis M, Thomas A, Schänzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 2008; 27:35-50.
24. Conte V. Victor Conte's letter to Dwain Chambers. In: Times Online (London) 2008.
25. Steiner A, Wagner RA. Insulin. ISP-Verlag, Arnsberg 2002; 3:4-73.
26. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W. Qualitative Determination of Synthetic Analogues of Insulin in Human Plasma by Immunoaffinity Purification and Liquid Chromatography-Tandem Mass Spectrometry for Doping Control Purposes. Anal Chem 2005; 77:3579-85.
27. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W. Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal Chem 2006; 78:1897-903.
28. Thomas A, Thevis M, Delahaut P, Bosseloir A, Schanzer W. Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. Anal Chem 2007; 79:2518-24.
29. Bruick RK, McKnight SL. Transcription. Oxygen sensing gets a second wind. Science 2002; 295:807-8.
30. Bruick R. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxiainducible transcription factor. Genes Dev 2003; 17:2614-23.
31. Safran M, Kaelin WG Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111:779-83.
32. Hirsilä M, Koivunen P, Günzler V, Kivirikko K, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003; 278:30772-80.
33. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107:43-54.
34. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294:1337-40.
35. 2-regulated prolyl hydroxylation. Science 2001; 292:468-72.
36. 2 sensing. Science 2001; 292:464-8.
37. Yu F, White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulussensitive proline hydroxylation. Proc Natl Acad Sci USA 2001; 98:9630-5.
38. Metzen E, Ratcliffe P. HIF hydroxylation and cellular oxygen sensing. Biol Chem 2004; 385:223-30.
39. Warnecke C, Griethe W, Weidemann A, Jurgensen J, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, Eckardt K. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003; 17:1186-8.
40. Bruick RK, McKnight SL. Building better vasculature. Genes Dev 2001; 15:2497-502.
41. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004; 43:649-59.
42. Ratcliffe P. From erythropoietin to oxygen: hypoxia-inducible factor hydroxylases and the hypoxia signal pathway. Blood Purif 2002; 20:445-50.
43. del Peso L, Castellanos M, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri M. The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem 2003; 278:48690-5.
44. Fibrogen Inc. Development Pipeline 2007; http://www.fibrogen.com/ pipeline/chart/anemia.html#mid.
45. Wang Q, Gou G, Guenzler V, Neff T, Klaus S, Turtle E, Molineaux C, Yeowell D, Lin A. Stimulation of erythropoiesis and treatment of anemia in rodents by oral administration of FG-2216, a novel HIF-prolyl hydroxylase inhibitor. J Am Soc Nephrol 2004; 15:773.
46. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, Lin A, Smith R, Rodgers GP, Donahue RE, Klaus SJ, Tisdale JF. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis and modest fetal hemoglobin expression in rhesus macaques. Blood 2007; 110:2140-7.
47. Stern. Inside the Blood Doping Investigation 2006; www.spiegel.de/ international/spiegel/0,1518,425939,00.html.
48. Thevis M, Kohler M, Schlörer N, Schänzer W. Gas Phase Reaction of Substituted Isoquinolines to Carboxylic Acids in Ion Trap and Triple Quadrupole Mass Spectrometers after Electrospray Ionization and Collision-Induced Dissociation. J Am Soc Mass Spectrom 2008; 19:151-8.
49. Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim S, Song LS, Rosemblit N, D'Armiento JM, Napolitano C, Memmi M, Priori SG, Lederer WJ, Marks AR. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113:829-40.
50. Wehrens XH, Marks AR. Altered function and regulation of cardiac ryanodine receptors in cardiac disease. Trends Biochem Sci 2003; 28:671-8.
51. Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 2004; 304:292-6.
52. Lehnart SE, Wehrens XH, Marks AR. Calstabin deficiency, ryanodine receptors and sudden cardiac death. Biochem Biophys Res Commun 2004; 322:1267-79.
53. Wehrens XH, Lehnart SE, Marks AR. Intracellular calcium release and cardiac disease. Annu Rev Physiol 2005; 67:69-98.
54. Wehrens XH, Lehnart SE, Marks AR. Ryanodine receptor-targeted anti-arrhythmic therapy. Ann NY Acad Sci 2005; 1047:366-75.
55. Bellinger AM, Reiken S, Dura M, Murphy PW, Deng SX, Landry DW, Nieman D, Lehnart SE, Samaru M, LaCampagne A, Marks AR. Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity. Proc Natl Acad Sci USA 2008; 105:2198-202.
56. Bellinger AM, Mongillo M, Marks AR. Stressed out: the skeletal muscle ryanodine receptor as a target of stress. J Clin Invest 2008; 118:445-53.
57. Rogers SA, Chen F, Talcott MR, Faulkner C, Thomas JM, Thevis M, Hammerman MR. Long-term engraftment following transplantation of pig pancreatic primordia into nonimmunosuppressed diabetic rhesus macaques. Xenotransplantation 2007; 14:591-602.